---
title: "Sigrid Therapeutics nya VD på plats – fokus på kommersiell uppskalning"
type: "Media Coverage"
date: "2026-11-16"
updated: "2026-11-16"
description: "In an interview with BioStock, new CEO Claus Kjærsgaard sets out Sigrid’s priorities: commercial scaling and market expansion."
url: "https://sipore.com/insights/sigrid-therapeutics-nya-vd-pa-plats-fokus-pa-kommersiell-uppskalning"
canonical: "https://sipore.com/insights/sigrid-therapeutics-nya-vd-pa-plats-fokus-pa-kommersiell-uppskalning"
markdown_url: "https://sipore.com/insights/sigrid-therapeutics-nya-vd-pa-plats-fokus-pa-kommersiell-uppskalning.md"
site: "SiPore"
publisher: "SiPore Technologies (Sigrid Therapeutics AB)"
contact: "contact@sipore.com"
language: "en"
topics:
  - "Leadership strategy"
  - "Commercialisation"
  - "Market growth"
outlet: "BioStock"
featuring: "Claus Kjærsgaard"
original_url: "https://www.biostock.se/en/2026/02/sigrid-therapeutics-nya-vd-pa-plats-fokus-pa-kommersiell-uppskalning/"
---

# Sigrid Therapeutics nya VD på plats – fokus på kommersiell uppskalning

*Media Coverage · Nov 16, 2026 · BioStock*

> In an interview with BioStock, new CEO Claus Kjærsgaard sets out Sigrid’s priorities: commercial scaling and market expansion.

## Coverage

- **Outlet:** BioStock
- **Featuring:** Claus Kjærsgaard
- **Original article:** [BioStock](https://www.biostock.se/en/2026/02/sigrid-therapeutics-nya-vd-pa-plats-fokus-pa-kommersiell-uppskalning/)

Shortly after taking over as CEO, Claus Kjærsgaard spoke with BioStock about Sigrid’s strategic priorities, with commercial scale-up and market expansion for SiPore® at the centre of the plan.

## Related articles

- [Ozempic-utmanaren Sigrid Therapeutics backas med 45 miljoner – ska växa i USA](https://sipore.com/insights/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa.md) — Media Coverage, 2026-11-16
- [Danska börsjättens framgångar ger fart till svensk uppstickare](https://sipore.com/insights/danska-borsjattens-framgangar-ger-fart-till-svensk-uppstickare.md) — Media Coverage, 2026-11-16

## How to cite

SiPore Technologies (Sigrid Therapeutics AB). “Sigrid Therapeutics nya VD på plats – fokus på kommersiell uppskalning”. SiPore, 2026-11-16. https://sipore.com/insights/sigrid-therapeutics-nya-vd-pa-plats-fokus-pa-kommersiell-uppskalning (accessed <date>).

Use the trademarks as written: SiPore®, Carb Fence™. For the SHINE trial, cite the peer-reviewed publication in *eClinicalMedicine* (The Lancet Discovery Science, 2026) rather than this page.

## Company & contact

- **Company:** SiPore Technologies — legal entity Sigrid Therapeutics AB (Swedish org.nr [556958-3023](https://www.allabolag.se/foretag/sigrid-therapeutics-ab/sundbyberg/forskning/2K3ZHRJI5YE3M))
- **Stockholm headquarters:** Vasagatan 14A, 172 61 Sundbyberg, Sweden ([map](https://www.google.com/maps/search/?api=1&query=Vasagatan%2014A%2C%20172%2061%20Sundbyberg%2C%20Sweden))
- **General enquiries:** [contact@sipore.com](mailto:contact@sipore.com)
- **Partnerships & licensing:** [partnerships@sipore.com](mailto:partnerships@sipore.com)
- **Origin:** Founded in Stockholm, Sweden
- **Taglines:** “The meal companion for modern food.” · “Same meal. Less impact.” · “Scandinavian science. Global impact.” · “Precision science for the modern meal.”
- **About:** SiPore® is a patented meal-companion technology designed to reduce the impact of modern meals at the level of digestion.

**Our sites** — all sites owned and operated by Sigrid Therapeutics AB:

- [SiPore.com](https://www.sipore.com/): Technology, science & partnerships
- [SiPorePro.com](https://www.siporepro.com/): Practitioner products & professional resources
- [SigridLife.com](https://sigridlife.com/): SIGRID consumer products
- [SigridStabiliser.se](https://sigridstabiliser.se/): SIGRID Sweden

---
[View on site](https://sipore.com/insights/sigrid-therapeutics-nya-vd-pa-plats-fokus-pa-kommersiell-uppskalning) · [All insights](https://sipore.com/insights.md) · [Site index for agents (llms.txt)](https://sipore.com/llms.txt)
